Recruiting Clinical Trial: Sonrotoclax Plus Zanubrutinib
March 20, 2024
A new phase 3 clinical trial is testing sonrotoclax, a new BCL2 inhibitor, in combination with zanubrutinib for CLL.
A new phase 3 clinical trial is testing sonrotoclax, a new BCL2 inhibitor, in combination with zanubrutinib for CLL.
Improving global representation in clinical trials is important for addressing enduring health disparities in underrepresented regions.
Despite mild persistent night sweats and disturbed sleep, I am enjoying and learning much at iwCLL (international workshop on CLL) in Boston.
Now there is a new trial (SUPERNOVA) of an updated mix of monoclonal antibodies that hopes to provide durable protection against present and future variants of concerns.
It’s an immune therapy because we harness our immune system to kill the cancer. No toxic chemotherapy.
The Food and Drug Administration (FDA)‘s draft guidance on clinical outcome assessments (COA) gave CLL Society an opportunity to share with the Agency why CLL can be a difficult area for research & development (R&D), and that, as a chronic blood cancer, treatment value from a patient’s perspective might turn more towards durability of response.
Very complex, promising research is currently underway to use humanized bispecific single-domain antibodies (bsVHH). But, unfortunately, harnessing the immune system can get very complicated. This article introduces an experimental antibody with a novel approach to fighting CLL / SLL.
What follows is our patient-friendly summary of this research.: BMF-219, an irreversible menin inhibitor that demonstrated strong preclinical activity against chronic lymphocytic leukemia or CLL patients’ specimens, including those with high-risk markers.
Discussion of a phase 3 clinical trial in progress, investigating the efficacy of the triple combination of ibrutinib plus venetoclax and obinutuzumab with response-dependent discontinuation.